Post-stroke central pain (PSCP) is a debilitating, refractory disorder
severely affecting one's quality of life (QOL). Various treatment
modalities have been used to treat this disorder, including medications,
surgical procedures, and non-invasive brain stimulation. Currently,
there are mainly two surgical procedures for PSCP: motor
cortex stimulation (MCS) and deep brain stimulation (DBS). Of
these, motor cortex stimulation (MCS) is the only surgical procedure
approved by the food and drug administration (FDA) in the United
States. Since the application of MCS was first reported by Tsubokawa
et al. [1], several authors have noted its efficacy. Conversely, only a
few reports have observed favorable outcomes with DBS for PSCP